Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
4
Bullish
6
Bearish
35
Neutral
4
Bullish
7
Bearish
31
Neutral
0
Bullish
1
Bearish
31
Neutral
0
Bullish
1
Bearish
31
Neutral
0
Bullish
1
Bearish
31
Neutral
0
Bullish
1
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
3B BlackBio Dx Limited is an Indian biotech and agrochemicals company manufacturing molecular diagnostic kits (TRUPCR), rapid tests (TRURAPID), NGS assays (TRUNGS), dPCR products and legacy agrochemical formulations; it also owns European operations through TRUPCR Europe and the acquired Coris BioConcept, combining R&D-led diagnostics with government-facing agro-business channels under a unified corporate group.
The group reported consolidated Q1 FY2026-27 revenue of ₹3,349.08 lakh (including Coris), up materially year-on-year, while consolidated profitability was depressed by Coris negative EBITDA; excluding Coris the MDx business showed higher PAT and EPS, indicating core Indian operations remain profitable and Coris is the integration-driven drag in near-term consolidated margins.
3B claims approximately 15% share of an estimated ₹500–600 crore Indian molecular diagnostics TAM and operates across 70+ countries, with TRUPCR Europe driving European acceptance; this mix delivers both domestic government tender exposure and diversified export channels, enabling management to target 15–20% growth driven by product launches, tenders and international distributor expansion.
R&D and regulatory credentials are central: over 120 assays developed, ISO 13485 certification, CE-IVD/IVDR alignment, CDSCO licensing and prior US FDA EUA for COVID-19. These credentials, plus newly launched AMR rapid tests, NGS panels and dPCR assays, give 3B BlackBio Dx Limited a differentiated, broad product portfolio that supports tender wins, reagent-rental contracts and reagent-driven recurring revenue.
Healthcare Services
Healthcare Service Provider
1,125 Cr
Moderate Risk
20.0
59.8
0.9
3.5
1,750.00
1,083.50
Sales CAGR
Profit CAGR
ROE
ROCE
3B Blackbio DX Ltd (3BBLACKBIO) is currently trading at 1,303.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
3B BlackBio Dx Limited is an Indian biotech and agrochemicals company manufacturing molecular diagnostic kits (TRUPCR), rapid tests (TRURAPID), NGS assays (TRUNGS), dPCR products and legacy agrochemical formulations; it also owns European operations through TRUPCR Europe and the acquired Coris BioConcept, combining R&D-led diagnostics with government-facing agro-business channels under a unified corporate group. The group reported consolidated Q1 FY2026-27 revenue of ₹3,349.08 lakh (including Coris), up materially year-on-year, while consolidated profitability was depressed by Coris negative EBITDA; excluding Coris the MDx business showed higher PAT and EPS, indicating core Indian operations remain profitable and Coris is the integration-driven drag in near-term consolidated margins. 3B claims approximately 15% share of an estimated ₹500–600 crore Indian molecular diagnostics TAM and operates across 70+ countries, with TRUPCR Europe driving European acceptance; this mix delivers both domestic government tender exposure and diversified export channels, enabling management to target 15–20% growth driven by product launches, tenders and international distributor expansion. R&D and regulatory credentials are central: over 120 assays developed, ISO 13485 certification, CE-IVD/IVDR alignment, CDSCO licensing and prior US FDA EUA for COVID-19. These credentials, plus newly launched AMR rapid tests, NGS panels and dPCR assays, give 3B BlackBio Dx Limited a differentiated, broad product portfolio that supports tender wins, reagent-rental contracts and reagent-driven recurring revenue.
Over the past 52 weeks, 3B Blackbio DX Ltd has traded between a low of ₹1,083.50 and a high of ₹1,750.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
3B Blackbio DX Ltd has a market capitalization of approximately 1,125.06. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
3B Blackbio DX Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.00 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,125.06 Cr, 3B Blackbio DX Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
3B Blackbio DX Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of 3B Blackbio DX Ltd is 20.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The 54th AGM is scheduled for September 29, 2026 at 11:30 am IST and will be held via video conferencing or other audio-visual means.
The board meeting to consider and approve the unaudited Q1 FY27 standalone and consolidated results is scheduled for August 13, 2026, at 3:00 P.M., per the BSE filing.
FY26 consolidated revenue from operations was ₹141.92 crore and consolidated PAT was ₹59.93 crore, versus ₹96.47 crore and ₹47.69 crore in FY25.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
483.60 | 1,569 Cr | 15.99 | 1.51 | 0.41 | 9.45 | 10.31 | 4.75 | ||
1310.85 | 1,125 Cr | 20.00 | 3.47 | 0.38 | 18.06 | 23.58 | 14.88 | ||
273.65 | 870 Cr | -33.42 | 1.36 | 0.00 | 0.30 | -0.07 | -2.78 | ||
396.65 | 775 Cr | 12.41 | 5.49 | 0.00 | 49.21 | 65.70 | 28.96 | ||
105.60 | 769 Cr | 33.20 | 5.05 | 0.00 | 16.06 | 20.16 | 11.99 | ||
401.70 | 732 Cr | 28.72 | 5.32 | 0.00 | 17.95 | 19.36 | 14.00 | ||
234.40 | 573 Cr | 20.32 | 3.37 | 0.00 | 11.34 | 20.76 | 7.42 | ||
| Median: 7 Co. | — | 396.65 | 775 Cr | 20.00 | 3.47 | 0.00 | 16.06 | 20.16 | 11.99 |
